feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Generic CF Drug Offers Hope at Fraction of Cost

Generic CF Drug Offers Hope at Fraction of Cost

7 Jan

•

Summary

  • A generic cystic fibrosis drug will cost $2,000 annually, a 99.5% price reduction.
  • The new treatment is produced by Bangladeshi company Beximco, available from Spring 2026.
  • Patient advocacy groups drove the development of this affordable life-saving medication.
Generic CF Drug Offers Hope at Fraction of Cost

A significant reduction in the cost of cystic fibrosis medication is bringing renewed hope to patients worldwide. A Bangladeshi pharmaceutical company, Beximco, is set to release Triko, a generic version of a vital CFTR modulator drug, for an estimated annual cost of $2,000 for adults and $6,375 for children. This represents a dramatic 99.5% price decrease from the original patented treatment.

This advancement is largely attributed to persistent advocacy from patient groups, who have campaigned for years against the prohibitive pricing of essential cystic fibrosis therapies. The original drug, ETI (elexacaftor/tezacaftor/ivacaftor), was priced at $370,000 annually by Vertex Pharmaceuticals. The new generic version, Triko, is scheduled for availability from Spring 2026, following successful collaboration between advocacy groups like Just Treatment and Beximco.

trending

Australia influenza cases rising sharply

trending

PG&E substation fires investigated

trending

Long COVID symptoms overlap

trending

NASA ISS spacewalks in January

trending

Earthquake near Tennessee, North Carolina

trending

UVA basketball player injured

trending

Tornado warning in Oklahoma

trending

Dallas weather: cooler temperatures

trending

Cautious range-bound stock market ahead

While Vertex Pharmaceuticals maintains its medicines are available in over 60 countries, the new generic option aims to address profound global disparities in treatment access. Bangladesh's status as a "least developed country" facilitates Beximco's production and export of the generic drug, circumventing some international intellectual property laws. Further cost reductions are anticipated with a reduced dosing protocol.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The new generic cystic fibrosis drug is called Triko, manufactured by Beximco.
The generic drug is expected to cost around $2,000 annually for adults and $6,375 for children, a significant reduction from the original price.
The generic cystic fibrosis drug, Triko, is anticipated to be available from Spring 2026.

Read more news on

Healthside-arrow

You may also like

Art Heals: Cancer Patients Find Peace in Painting

5 Jan • 24 reads

article image

Drug Price Hikes Looming: 350+ Meds Affected Jan 1

1 Jan • 30 reads

article image

Cancer Patients Fund Own Chemo Amid NHS Wait Woes

21 Dec, 2025 • 105 reads

article image

Cancer Patient Misses Parties Due to Chemo Side Effects

20 Dec, 2025 • 104 reads

article image

Alcohol's Cancer Link: New Study Shifts Focus

16 Dec, 2025 • 131 reads

article image